Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Apellis Pharmaceuticals Inc

Healthcare US APLS

NoneUSD
0.00(0%)

Last update at 2026-06-05T21:04:10.685071Z

Day Range

--
LowHigh

52 Week Range

16.1040.95
LowHigh

Fundamentals

  • Previous Close 3.38
  • Market Cap5233.84M
  • VolumeNone
  • P/E Ratio227.44
  • Dividend Yield-%
  • EBITDA56.98M
  • Revenue TTM1003.78M
  • Revenue Per Share TTM7.96
  • Gross Profit TTM 605.69M
  • Diluted EPS TTM0.18

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 24.11M -196.71600M -526.49600M -651.50300M -746.00200M
Minority interest - - - - -
Net income 22.39M -197.87800M -528.62800M -652.17200M -746.35400M
Selling general administrative 550.26M 417.75M 500.81M 277.16M 176.77M
Selling and marketing expenses - 83.30M 1.70M - -
Gross profit 901.55M 663.64M 338.08M 69.79M 61.36M
Reconciled depreciation 1.56M 1.80M 1.70M 1.49M 1.49M
Ebit 68.44M -156.32500M -496.91500M -594.61300M -536.27700M
Ebitda 70.00M -154.52800M -495.21100M -584.50000M -533.00500M
Depreciation and amortization 1.56M 1.80M 1.70M 10.11M 3.27M
Non operating income net other - - - - -
Operating income 55.43M -164.97900M -517.12100M -594.61300M -536.27700M
Other operating expenses 948.36M 946.35M 913.71M 670.03M 602.84M
Interest expense 44.33M 40.39M 29.58M 32.63M 13.24M
Tax provision 1.72M 1.16M 2.13M 0.67M 0.35M
Interest income 13.14M 12.77M 20.93M 8.91M 0.42M
Net interest income -31.18400M -27.61800M -8.64800M -23.71200M -12.82300M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.72M 1.16M 2.13M 0.67M 0.35M
Total revenue 1003.78M 781.37M 396.59M 75.42M 66.56M
Total operating expenses 846.12M 828.62M 855.20M 664.40M 597.64M
Cost of revenue 102.24M 117.72M 58.51M 5.64M 5.20M
Total other income expense net -31.31700M -31.73700M -9.37500M -56.89000M -209.72500M
Discontinued operations - - - - -
Net income from continuing ops 22.39M -197.87800M -528.62800M -652.17200M -746.35400M
Net income applicable to common shares - - - -652.17200M -746.35400M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1075.26M 885.05M 788.73M 760.22M 881.76M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 38.30M 18.61M 61.23M 36.66M 70.68M
Total liab 705.11M 656.51M 594.21M 590.35M 683.10M
Total stockholder equity 370.15M 228.54M 194.52M 169.87M 198.66M
Deferred long term liab - - - - -
Other current liab 166.05M 140.18M 203.64M 124.64M 7.58M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01000M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01000M
Retained earnings -3012.97800M -3035.36600M -2837.48800M -2308.86000M -1656.68800M
Other liab - - - 315.65M 345.15M
Good will - - - - -
Other assets - - - 15.80M 31.64M
Cash 467.76M 411.29M 352.30M 551.80M 640.19M
Cash and equivalents - - - - -
Total current liabilities 323.60M 185.51M 247.59M 167.61M 131.85M
Current deferred revenue - - - - 103.24M
Net debt 18.55M 58.49M -241.37100M -439.08800M -429.97200M
Short term debt 100.75M 6.75M 6.44M 5.62M 4.12M
Short long term debt 93.66M - - - -
Short long term debt total 486.31M 469.78M 110.93M 112.71M 210.22M
Other stockholder equity 3385.22M 3267.20M 3035.54M 2479.60M 1857.43M
Property plant equipment - - - 24.89M 26.08M
Total current assets 1014.84M 788.95M 766.33M 719.52M 824.05M
Long term investments - - - - -
Net tangible assets - - - 169.87M 198.66M
Short term investments - 4.85M 4.35M 0.00000M 60.36M
Net receivables 366.22M 271.72M 206.44M 7.73M 10.10M
Long term debt 361.66M 452.83M 93.03M 92.74M 189.02M
Inventory 142.56M 82.48M 146.36M 85.71M 16.29M
Accounts payable 56.80M 38.57M 37.52M 37.34M 16.91M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -2.10300M -3.30800M -3.54200M -0.87500M -2.09000M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 40.51M 77.06M 1.31M 15.80M 31.64M
Deferred long term asset charges - - - - -
Non current assets total 60.42M 96.10M 22.40M 40.69M 57.72M
Capital lease obligations 19.03M 16.95M 17.89M 19.98M 21.20M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.40300M -0.67400M 59.89M 248.72M
Change to liabilities - - - 18.69M 10.49M
Total cashflows from investing activities -0.31300M -0.40300M -0.67400M 59.89M 247.62M
Net borrowings 0.00000M 365.45M 0.00000M - -
Total cash from financing activities 8.88M 149.24M 394.50M 365.66M 392.24M
Change to operating activities - - - 32.63M -77.58900M
Net income 22.39M -197.87800M -528.62800M -652.17200M -746.35400M
Change in cash 55.15M 60.31M -200.77500M -88.68100M 74.71M
Begin period cash flow 412.61M 352.30M 553.07M 641.75M 567.04M
End period cash flow 467.76M 412.61M 352.30M 553.07M 641.75M
Total cash from operating activities 45.33M -87.86600M -594.73500M -513.74500M -563.12600M
Issuance of capital stock 0.00000M 0.00000M 384.39M 380.12M 380.36M
Depreciation 1.56M 1.80M 1.70M 1.49M 1.49M
Other cashflows from investing activities -0.31300M - 0.10M - -
Dividends paid - - - - -
Change to inventory -15.26700M -10.75500M -60.64700M -69.39700M -16.31700M
Change to account receivables -101.27900M -58.48400M -198.71500M 2.38M -10.10300M
Sale purchase of stock - 4.51M -11.04000M 4.24M 2.97M
Other cashflows from financing activities -0.01100M -235.04100M 10.11M -18.69900M 8.90M
Change to netincome - - - 152.11M 274.29M
Capital expenditures 0.31M 0.40M 0.77M 1.52M 1.10M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -85.11800M -18.35700M -200.16900M -15.69800M -93.52200M
Stock based compensation 104.00M 114.13M 105.94M 91.08M 70.67M
Other non cash items 108.06M 12.44M 26.41M 61.55M 6.33M
Free cash flow 45.01M -88.26900M -595.50800M -515.26900M -564.22900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
APLS
Apellis Pharmaceuticals Inc		 - -% - 227.44 46.30 5.21 14.14 5.22 74.88
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts.

Apellis Pharmaceuticals Inc

100 Fifth Avenue, Waltham, MA, United States, 02451

Key Executives

Name Title Year Born
Dr. Cedric Francois M.D., Ph.D. Co-Founder, Pres, CEO & Director 1972
Dr. Pascal Deschatelets Ph.D. Co-Founder & Chief Scientific Officer 1970
Dr. Federico Grossi M.D., Ph.D. Co-Founder & Chief Medical Officer 1974
Mr. Alec Machiels J.D., MBA Co-Founder & Director 1973
Mr. Timothy E. Sullivan CFO & Treasurer 1971
Mr. Adam J. Townsend Chief Commercial Officer 1977
Ms. Nur Nicholson Chief Technical Operations Officer NA
Mr. James G. Chopas CPA VP, Corp. Controller & Chief Accounting Officer 1966
Ms. Meredith Kaya Sr. VP, Investor Relations & Strategic Fin. NA
Mr. David O. Watson Esq., J.D. Gen. Counsel 1973

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.